# Avelumab as Neoadjuvant Therapy in Subjects With Urothelial Muscle Invasive Bladder Cancers (AURA Trial)

> **NCT03674424** · PHASE2 · COMPLETED · sponsor: **Jules Bordet Institute** · enrollment: 137 (actual)

## Conditions studied

- Non-metastatic Muscle Invasive Bladder Cancer

## Interventions

- **DRUG:** Avelumab
- **PROCEDURE:** cystectomy
- **COMBINATION_PRODUCT:** CG
- **COMBINATION_PRODUCT:** DD-MVAC
- **COMBINATION_PRODUCT:** PG

## Key facts

- **NCT ID:** NCT03674424
- **Lead sponsor:** Jules Bordet Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-01
- **Primary completion:** 2021-12-07
- **Final completion:** 2025-01-30
- **Target enrollment:** 137 (ACTUAL)
- **Last updated:** 2025-02-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03674424

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03674424, "Avelumab as Neoadjuvant Therapy in Subjects With Urothelial Muscle Invasive Bladder Cancers (AURA Trial)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03674424. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*